financetom
Business
financetom
/
Business
/
Update: Five Below Fiscal Q4 Earnings, Revenue Miss Forecasts; Shares Tumble Premarket
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Five Below Fiscal Q4 Earnings, Revenue Miss Forecasts; Shares Tumble Premarket
Mar 21, 2024 4:21 AM

06:46 AM EDT, 03/21/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Five Below's ( FIVE ) shares fell more than 12% in premarket activity Thursday after the company's fiscal Q4 earnings and revenue growth lagged forecasts.

The company reported fiscal Q4 earnings late Wednesday of $3.65 per diluted share, up from $3.07 a year earlier.

Analysts polled by Capital IQ expected $3.78.

Net sales for the quarter ended Feb. 3 was $1.34 billion, up from $1.12 billion a year earlier. Analysts surveyed by Capital IQ expected $1.35 billion.

The company said it expects fiscal Q1 EPS of $0.58 to $0.69 and net sales ranging from $826 million to $846 million. Analysts in a Capital IQ poll expect $0.77 and $851.5 million, respectively.

For fiscal 2024, it expects EPS of $5.71 to $6.22 and net sales in the range of $3.97 billion to $4.07 billion. Analysts in a Capital IQ survey expect $6.46 and $4.11 billion, respectively.

Price: 182.33, Change: -26.64, Percent Change: -12.75

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
I-Mab Cancer Drug Trial Shows 'Encouraging' Topline Data
I-Mab Cancer Drug Trial Shows 'Encouraging' Topline Data
Sep 16, 2024
04:30 PM EDT, 09/16/2024 (MT Newswires) -- I-Mab ( IMAB ) said Monday it has seen encouraging topline data from an ongoing phase 1 trial of givastomig in people with advanced cancers, especially gastric cancers. The results were showcased at the congress of the European Society for Medical Oncology, or ESMO, which is taking place in Barcelona, Spain, the company...
Atlassian Insider Sold Shares Worth $1,305,154, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,305,154, According to a Recent SEC Filing
Sep 16, 2024
04:30 PM EDT, 09/16/2024 (MT Newswires) -- Scott Farquhar, 10% Owner, Director, on September 13, 2024, sold 7,948 shares in Atlassian ( TEAM ) for $1,305,154. Following the Form 4 filing with the SEC, Farquhar has control over a total of 87,428 shares of the company, with 87,428 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024006821/xslF345X05/primarydocument.xml ...
Nvidia Insider Sold Shares Worth $28,551,919, According to a Recent SEC Filing
Nvidia Insider Sold Shares Worth $28,551,919, According to a Recent SEC Filing
Sep 16, 2024
04:30 PM EDT, 09/16/2024 (MT Newswires) -- Jen Hsun Huang, Director, President and CEO, on September 12, 2024, sold 240,000 shares in Nvidia ( NVDA ) for $28,551,919. Following the Form 4 filing with the SEC, Huang has control over a total of 861,019,236 shares of the company, with 75,415,836 shares held directly and 785,603,400 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1045810/000104581024000274/xslF345X05/wk-form4_1726518135.xml...
Impinj Insider Sold Shares Worth $665,126, According to a Recent SEC Filing
Impinj Insider Sold Shares Worth $665,126, According to a Recent SEC Filing
Sep 16, 2024
04:33 PM EDT, 09/16/2024 (MT Newswires) -- Umesh Padval, Director, on September 13, 2024, sold 3,529 shares in Impinj ( PI ) for $665,126. Following the Form 4 filing with the SEC, Padval has control over a total of 1,729 shares of the company, with 1,729 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1114995/000141588924023440/xslF345X05/form4-09162024_080916.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved